Department of Biochemistry and Diet Therapy, School of Nutrition & Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Sci Prog. 2024 Jul-Sep;107(3):368504241259299. doi: 10.1177/00368504241259299.
Inflammatory processes are key factors in pathological events associated with severe traumatic brain injury (STBI). The aim of this trial was to determine the effect of probiotics on anthropometric measures, disease severity, inflammatory markers, and T cells in patients with STBI.
Forty adult patients with STBI were enrolled in this parallel randomized, double-blind, placebo-controlled trial. Energy and protein status, Acute Physiology and Chronic Health Evaluation (APACHE II) score, Sequential Organ Failure Assessment (SOFA), interleukin 10 (IL-10), interleukin 1β (IL-1β), tumor necrosis factor-alpha (TNF-α), transforming growth factor beta (TGF-β), T-helper 17 (Th17), and T- Regulator (T-reg) cells were assessed at baseline (day 1), and week 2 (day 14) for each patient.
Probiotic supplementation led to a substantial reduction in the serum levels of TNF-α (from 10.15 ± 6.52 to 5.05 ± 3.27) ( = 0.034), IL-1β (from 11.84 ± 7.74 to 5.87 ± 3.77) ( < 0.001), and Th17 cells (from 5.19 ± 1.69 to 2.67 ± 1.89) ( < 0.001) and a substantial increase in the serum levels of IL-10 (from 3.35 ± 1.45 to 6.17 ± 2.04) ( = 0.038), TGF-β (from 30.5 ± 15.27 to 46.25 ± 21.05) ( < 0.001), and T-reg cells (from 2.83 ± 1.43 to 4.29 ± 1.89) ( < 0.001) compared with the placebo group. Furthermore, no notable changes were observed in energy and protein intake and also, terms of SOFA and APACHE II scores following probiotic treatment compared with the placebo.
Probiotics could reduce inflammation and improve cellular immunity and may be considered as an adjunctive therapy in STBI patients.
炎症过程是与严重创伤性脑损伤（STBI）相关的病理事件的关键因素。本试验的目的是确定益生菌对 STBI 患者的人体测量指标、疾病严重程度、炎症标志物和 T 细胞的影响。
这项平行随机、双盲、安慰剂对照试验纳入了 40 名成年 STBI 患者。在每个患者的基线（第 1 天）和第 2 周（第 14 天）评估能量和蛋白质状态、急性生理学和慢性健康评估（APACHE II）评分、序贯器官衰竭评估（SOFA）、白细胞介素 10（IL-10）、白细胞介素 1β（IL-1β）、肿瘤坏死因子-α（TNF-α）、转化生长因子-β（TGF-β）、辅助性 T 细胞 17（Th17）和 T 调节细胞（T-reg）。
益生菌补充剂可显著降低 TNF-α 血清水平（从 10.15±6.52 降至 5.05±3.27）（=0.034）、IL-1β 血清水平（从 11.84±7.74 降至 5.87±3.77）（<0.001）和 Th17 细胞（从 5.19±1.69 降至 2.67±1.89）（<0.001），同时显著增加 IL-10 血清水平（从 3.35±1.45 升至 6.17±2.04）（=0.038）、TGF-β 血清水平（从 30.5±15.27 升至 46.25±21.05）（<0.001）和 T-reg 细胞（从 2.83±1.43 升至 4.29±1.89）（<0.001），与安慰剂组相比。此外，与安慰剂相比，益生菌治疗后，能量和蛋白质摄入以及 SOFA 和 APACHE II 评分也没有明显变化。
益生菌可降低炎症反应，改善细胞免疫功能，可作为 STBI 患者的辅助治疗方法。
